A Research Plan for a Randomised, Single-blind, Parallel Group Controlled Trial in Rural Malawi, Testing the Health Effects of Supplementing Maternal Diet During Pregnancy and Lactation and Infant Diet From 6 to 18 Months of Age With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Infant Malnutrition
- Sponsor
- Tampere University
- Enrollment
- 1391
- Locations
- 1
- Primary Endpoint
- Birth weight
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The use of lipid-based nutrients (LNS), such as Nutributter or fortified spread (FS), have been associated with improved growth and development outcomes among infants in Ghana and Malawi. Modified versions of such supplements have been developed to improve their nutrient density and quality and to lower their costs. Such modified products have proven acceptable to pregnant women in Malawi and Ghana. In the present trial, the investigators aim to test the effect of LNS on pregnancy and child outcomes, when given during pregnant and lactating women and their infants from 6 to 18 months of age. In control groups, participants will receive either iron+folate tables during pregnancy only or multiple micronutrient tablets during pregnancy and first six months of lactations. The main hypothesis to be tested suggests that the mean length-for-age Z-score (LAZ) of 18-month-old infants who received LNS between 6 and 18 months of age and whose mothers were provided with LNS during pregnancy and the first 6 months of lactation is higher than the mean LAZ score of same age infants who received no dietary supplements and whose mothers received iron-folate supplementation during pregnancy only.
To detect the long-term effect of the LNS supplementation, we now propose to conduct a follow-up study when the children are 9 years old, to see if the intervention had effect on children's growth, cardiometabolic and respiratory status and neurocognitive development.
Detailed Description
Pregnant women will be identified from the antenatal clinics of 4 governmental and 2 other health centres. A total of 1400 women meeting set criteria will be randomised into receiving one of the following interventions: 1) Iron and folic acid supplementation to the mother during pregnancy only (IFA group), 2). Multiple micronutrient supplementation to the mother during pregnancy and six months thereafter (MMN group), 3) Lipid-based nutrient supplements to the mother during pregnancy and six months thereafter and to the child from 6 to 18 months of age (LNS group). The mothers will receive LNS or the multiple micronutrients at 2-weekly intervals at their homes during pregnancy and weekly during first six months of lactation. Children in the LNS group will receive LNS weekly, starting at 6 months. Mothers will be medically examined and tested for defined laboratory parameters at enrolment, at 36 gestation weeks, at birth or soon thereafter, and at 6 months after delivery. Child size will be assessed at birth or soon thereafter and at 3, 6, 12, and 18 months of age. The mothers will undergo a morbidity evaluation fortnightly and the children weekly. 864 mother-infant pairs will undergo the complete intervention and follow-up, as described above. The remaining 536 participants will undergo a simplified intervention and follow-up, in which there are no interventions after birth and the child follow-up consists only of 4 3 health centre and one home visits; first at 1 week, then at six weeks (at home) and at 6 and 18 months of age. A sub-study on the the development of intestinal microbiome was added in August 2011. This entails the collection of stool samples from the mother at 1 month after delivery, breast milk samples from the mothers at 1, 3, and 6 months after delivery and stool and urine samples from the children repeated during the a8 months of intervention. The aim of this subproject is to study the development of the infants' intestinal microbiota, its predictors and its association to child growth and other health outcomes. At the same time point, the sample size was reduced from 2400 to 1400 participants (due to constraints in funding). A one year post-intervention follow-up for participants in the complete follow-up was added to the study protocol in August 2013. The intervention will be stopped when the participants are 18 months old. Thereafter, there will be an anthropometrirc assessment and blood and urine draw at the study clinic at 24 and 30 months of age. Stool samples will be collected from the participants at the age of 21, 24, 27 and 30 months, to study the development of intestinal microbiome. In a follow-up study, when the children are 10 years old, we will assess: 1. child growth using standard anthropometric measures, 2. cardiometabolic health by measuring body composition, blood pressure and plasma lipids, 3. neurodevelopment by measuring neural function, cognitive skills and education attainment using EE and EGMA and Raven's questionnaires, 4. lung function with spirometry and allergy symptoms and asthma using ISAAC questionnaire.
Investigators
Per Ashorn
Professor of Paediatrics
Tampere University
Eligibility Criteria
Inclusion Criteria
- •Ultrasound confirmed pregnancy of no more than 20 completed gestation weeks
- •Permanent resident of Mangochi District Hospital, Malindi Hospital or Lungwena Health Centre catchment areas
- •Availability during the period of the study
- •Signed informed consent
Exclusion Criteria
- •Less than 15 years of age
- •Need for frequent medical attention due to a chronic health condition
- •Diagnosed asthma treated with regular medication
- •Severe illness warranting hospital referral
- •History of allergy towards peanuts
- •History of anaphylaxis or serious allergic reaction to any substance, requiring emergency medical care
- •Pregnancy complications evident at enrolment visit (moderate to severe oedema, blood Hb concentration \< 5 g / dl, systolic blood pressure (BP) \> 160 mmHg or diastolic BP \> 100 mmHg)
- •Earlier participation in the iLiNS-DYAD-M trial
- •Concurrent participation in any other clinical trial
Outcomes
Primary Outcomes
Birth weight
Time Frame: approx 20 weeks after enrollment (within 48 hours)
Newborn length
Time Frame: At 1 week of age
Length for age Z-score (LAZ) at 18 months of age
Time Frame: 12 months after enrollment (age 18 months)
Secondary Outcomes
- Blood pressure(At 36 wk gestation)
- Depressive symptoms (which may be related to essential fatty acid status)(At 4 weeks and at 6 months postpartum)
- Anthropometric status (weight, BMI, mid upper arm circumference and triceps and sub-scapular skin-fold thickness)(at ~ 36 wk gestation and 6 months postpartum)
- Gestational age at delivery, proportion of preterm deliveries(At delivery)
- Proportion of low birth weight babies(At birth)
- Anaemia and iron status (Hb, ZPP, transferrin receptor), other micronutrient status (vitamin A, B-vitamins, zinc), malarial antigen(At ~ 36 wk gestation and 6 mo postpartum)
- Red blood cell essential fatty acid status(At ~ 36 wk gestation)
- Urinary iodine(At ~ 36 wk gestation)
- Total plasma cholesterol concentration(At ~ 36 wk gestation)
- Basal salivary cortisol concentration(At 6, 12 and 18 months of age)
- Breast milk composition (essential fatty acids, vitamin A, B-vitamins)(At 6 mo postpartum)
- Placental malaria histology(At delivery)
- Incidence of febrile malaria episodes(During pregnancy)
- Peripheral blood malaria parasitaemia(At 32 wk gestation and at delivery)
- Evidence of defined bacteria in the chorionic membranes at delivery (quantitative DNA amplification method)(At birth)
- Prevalence of Neisseria gonorrhoea, Chlamydia trachomatis, in swab samples taken from maternal uterine cervix(qualitative DNA amplification method)(At one week after delivery)
- Prevalence of bacterial vaginosis, Trichomonas vaginalis, or candidiasis, in swab samples taken from maternal vagina(direct microscopy)(At one week after delivery)
- Anthropometric infant status (weight, length, head circumference and mid upper arm circumference)(At 7 days of age and at 6, 12 and 18 months of age. After the intervention at 24 and 30 months and at 10 y of age.)
- Malaria immunity(At 6 and 18 months of age)
- Infant anaemia and iron status (Hb, ZPP), micronutrient (vitamin A, B-vitamins) and essential fatty acids status, evidence of acute inflammation (CRP, AGP), and malarial antigen and microscopy(At 6 and 18 months of age)
- Incidence of neonatal hospitalizations(At or before age 28 days)
- Clinical morbidity(Between 0 and 18 months of age)
- Child feeding practices and maternal report of child sleep patterns(At 6, 12 and 18 months of age)
- Antibody response to measles vaccination(At 18 months of age)
- Cortisol response to acute stress(At 6 and 18 months of age)
- Achievement of five motor milestones and four other developmental milestones(From 0 to 18 mo)
- Neurobehavioral development(At 18 months of age)
- Incidence of serious adverse events(During pregnancy and 18 months of infant follow-up)
- Prevalence of maternal periodontitis(At one week after delivery)
- Maternal cognition(6 months after delivery)
- Mother - child interaction(6 months after delivery)
- The composition of intestinal microbiota(1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months of child age)
- diastolic blood pressure(Child is 10 years)
- central blood pressure(Child is 10 years)
- pulse rate(Child is 10 years)
- vascular resistance(Child is 10 years)
- plasma concentration of glucose(Child is 10 years)
- plasma concentration of cholesterol(Child is 10 years)
- plasma concentration of HDL/LDL cholesterol(Child is 10 years)
- plasma concentration of triglycerides(Child is 10 years)
- plasma concentration of c-reactive protein(Child is 10 years)
- plasma concentration of alkaline phosphatase(Child is 10 years)
- plasma concentration of potassium(Child is 10 years)
- neural functioning(Child is 10 years)
- processing speed(Child is 10 years)
- plasma concentration of aspartyl alanine transferase(Child is 10 years)
- plasma concentration of sodium(Child is 10 years)
- Spirometry measures functional volume of the lungs(Child is 10 years)
- asthma symptoms(Child is 10 years)
- allergy symptoms(Child is 10 years)
- oculomotor reaction time(Child is 10 years)
- head circumference(Child is 10 years)
- plasma concentration of urate(Child is 10 years)
- academic achievement(Child is 10 years)
- height(Child is 10 years)
- sitting height(Child is 10 years)
- weight(Child is 10 years)
- mid-upper arm circumference(Child is 10 years)
- body composition(Child is 10 years)